Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of novel malaria vaccine antigen targeting multiple stages of the Plasmodium lifecycle.

Award Number: R21AI201869
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/03/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Development of novel malaria vaccine antigen targeting multiple stages of the Plasmodium lifecycle. - Development of a novel malaria vaccine antigen targeting multiple stages of the Plasmodium lifecycle. Project summary Previously, using a phage peptide display library technique, our group identified mimotope peptides that mimic the conformation of Plasmodium sporozoite ligands essential for liver infection. Notably, these small peptides elicit protective immunity by inducing antibodies that neutralize sporozoites. Using a similar approach, we identified two peptides, FG1 and MG1, which structurally mimic ligands employed by male and female gametes to facilitate parasite fertilization in the mosquito midgut. Antibodies generated against each peptide specifically bind to their corresponding gametes and markedly inhibit fertilization, thereby blocking mosquito transmission. Using the anti-MG1 antibody, we further identified the Plasmodium Heat-Shock- Protein 90 N’-terminal ATPase domain (HSP90N’) as the female gamete fertilization ligand and a potential transmission-blocking vaccine (TBV) antigen. We propose to 1) evaluate the transmission-blocking efficacy of the HSP90N’ domain and the MG1 peptide to select an optimal female-targeting antigen, and then fuse it with the male-targeting FG1 peptide to generate a dual-target TBV antigen; and 2) develop a multiple-stage vaccine antigen by linking the dual epitope TBV construct with our recently developed triple-epitope liver-stage vaccine antigen. The final fusion vaccine antigen will comprise: (i) a female gamete antigen (HSP90N’ or MG1), (ii) the FG1 peptide targeting male gametes, (iii) the PfCSP NPNA repeat peptide, (iv) the P39 peptide targeting sporozoite–Kupffer cell traversal, and (v) the HP1 peptide targeting sporozoite–hepatocyte invasion. We anticipate that this strategy will enhance malaria control by eliciting broad protective immunity through a single antigen targeting multiple essential epitopes across the Plasmodium life cycle.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $230,463 )
2026	2026	THE CORPORATION OF MERCER UNIVERSITY	1501 MERCER UNIVERSITY DR	MACON	GA	31207	BIBB	USA	Allergy and Infectious Diseases Research	000	1	7/6/2026	NEW	$230,463
														Subtotal = $230,463

Grand Total All Awards = $230,463

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of novel malaria vaccine antigen targeting multiple stages of the Plasmodium lifecycle.

Award Number: R21AI201869

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/03/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer